|

EXL01 Clinical Trials

3 actively recruiting trials

Pipeline

Phase 2: 2Phase 1/2: 1

Top Sponsors

  • University Hospital, Lille1
  • GERCOR - Multidisciplinary Oncology Cooperative Group1
  • Center Eugene Marquis1

Indications

  • Cancer3
  • Liver Disease1
  • Liver Cancer1
  • Gastric Cancer1
  • Hepatocellular Carcinoma1

Other3 trials

EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.
Phase 1/2
First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer
Phase 2
Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.